Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00658
|
|||||
Drug Name |
Fluphenazine
|
|||||
Synonyms |
1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; 1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-(9CI); 10-(3'-(4"-(beta-Hydroxyethyl)-1"-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3'-(4''-(beta-Hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-pipe razinyl)propyl)phenothiazine; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol dihydrochloride; 4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol; 4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol; Anatensol (TN); Apo-Fluphenazine; Dapotum; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Elinol; Enanthate (TN); Fludecate (TN); Flufenazin; Flufenazina; Flufenazina [DCIT]; Flunanthate (TN); Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazine (INN); Fluphenazine [INN:BAN]; Fluphenazine hydrochloride; Fluphenazinum; Fluphenazinum [INN-Latin]; Ftorphenazine; Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen (Tabl or elixir); Moditen Enanthate Injection (TN); Moditen Hcl; Omca (TN); Pacinol; Permitil (TN); Permitil Concentrate; Phthorphenazine; Prolixin (TN); Prolixin Concentrate; Prolixine; S94; SQ 4918; Sediten (TN); Selecten (TN); Sevinol; Sevinol (TN); Sinqualone (TN); Siqualine; Siqualon; Trancin (TN); Triflumethazine; Vespazine; Yespazine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Psychotic disorders [ICD11: 6A2Z] | Approved | [1] | |||
Therapeutic Class |
Antipsychotic Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C22H26F3N3OS
|
|||||
Canonical SMILES |
C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
|
|||||
InChI |
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
|
|||||
InChIKey |
PLDUPXSUYLZYBN-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 69-23-8
|
|||||
Pharmaceutical Properties | Molecular Weight | 437.5 | Topological Polar Surface Area | 55.2 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 6 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 8 | |||
XLogP |
4.4
|
|||||
PubChem CID | ||||||
PubChem SID |
10532904
, 11111179
, 11111180
, 11212325
, 11335686
, 11360925
, 11363183
, 11364798
, 11365745
, 11367360
, 11368307
, 11369922
, 11372419
, 11372962
, 11374514
, 11375522
, 11376469
, 11378089
, 11461897
, 11466348
, 11467468
, 11485013
, 11486275
, 11489015
, 11491235
, 11492643
, 11494103
, 14832617
, 24263032
, 26751625
, 29222507
, 46506645
, 47291093
, 47291094
, 47365145
, 47588956
, 47588957
, 47662238
, 47662239
, 47736435
, 47885368
, 48110419
, 48259193
, 48259194
, 5329924
, 606306
, 7979286
, 8152146
, 841998
, 9223
|
|||||
ChEBI ID |
CHEBI:5123
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | Fluphenazine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.